What is Leerink Partnrs’ Forecast for IQVIA FY2024 Earnings?

IQVIA Holdings Inc. (NYSE:IQV) – Equities research analysts at Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for IQVIA in a note issued to investors on Tuesday, November 19th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will earn $10.07 per share for the year, down from their previous estimate of $10.15. The consensus estimate for IQVIA’s current full-year earnings is $10.18 per share. Leerink Partnrs also issued estimates for IQVIA’s FY2025 earnings at $10.91 EPS.

IQV has been the topic of several other research reports. Robert W. Baird cut their price objective on IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. BTIG Research dropped their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft reduced their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Redburn Atlantic began coverage on shares of IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective on the stock. Finally, The Goldman Sachs Group reduced their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Stock Up 1.6 %

Shares of IQVIA stock opened at $194.38 on Wednesday. IQVIA has a 12-month low of $187.62 and a 12-month high of $261.73. The firm has a market capitalization of $35.28 billion, a PE ratio of 25.51, a price-to-earnings-growth ratio of 1.98 and a beta of 1.51. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock’s fifty day moving average is $224.22 and its 200-day moving average is $227.56.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 6.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On IQVIA

A number of large investors have recently added to or reduced their stakes in IQV. PGGM Investments boosted its stake in IQVIA by 55.8% during the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after purchasing an additional 4,326 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of IQVIA in the first quarter worth $3,365,000. Simplify Asset Management Inc. increased its position in IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after acquiring an additional 3,894 shares during the period. Raymond James & Associates raised its stake in IQVIA by 0.7% during the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after purchasing an additional 5,417 shares during the last quarter. Finally, Versor Investments LP bought a new stake in IQVIA in the 3rd quarter valued at $1,328,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.